DiaMedica Posts Narrower Loss in Q2

DiaMedica Therapeutics (DMAC) reported a Q2 2025 GAAP loss per share of $(0.18), exceeding analyst consensus, alongside positive interim Phase 2 results for its DM199 preeclampsia trial, which met all pre-specified safety and efficacy endpoints. A $30.1 million private placement in July 2025 significantly strengthened the company's balance sheet, extending its cash runway into the second half of 2027, despite increased research and development expenses. This financial bolstering and clinical advancement position DMAC to continue developing DM199 for high-unmet-need conditions like preeclampsia and acute ischemic stroke.

Analysis

DiaMedica Therapeutics (DMAC) presented a strategically positive quarter despite a widening net loss, which grew to $7.7 million from $5.1 million year-over-year. The company reported a GAAP loss per share of $(0.18), narrowly beating the analyst consensus estimate of $(0.19). This increased loss was driven by a necessary and significant 48.7% year-over-year rise in R&D expenses to $5.8 million, reflecting intensified activity in its late-stage clinical trials. The critical developments offsetting this cash burn were a successful $30.1 million private placement in July 2025 and highly encouraging clinical data. The financing extends the company's cash runway into the second half of 2027, providing sufficient capital to reach key inflection points. Clinically, the company announced positive interim results for its lead candidate, DM199, in a Phase 2 trial for preeclampsia, meeting all pre-specified safety and efficacy endpoints. Key findings included a statistically significant reduction in blood pressure and, crucially, no evidence of placental transfer, a vital safety metric for this patient population. While the ReMEDy2 stroke trial continues toward an interim analysis in Q2 2026, the preeclampsia data represents a significant de-risking event for a core part of the pipeline.

Key Decisions for Investors

• The combination of positive Phase 2 preeclampsia data and a secured cash runway through H2 2027 significantly strengthens the company's fundamental position, warranting a re-evaluation of its risk profile.
• Investors should closely monitor upcoming catalysts, particularly the U.S. IND filing for DM199 in preeclampsia and the interim data from the Phase 2/3 stroke trial expected in Q2 2026, as these are primary valuation drivers.
• While the financial position is now robust, the 48.7% increase in R&D spending should be tracked to ensure cash burn remains consistent with the projected runway.
• The recent inclusion in the Russell 2000/3000 indexes could lead to increased institutional interest and liquidity, providing a potential tailwind for the stock's visibility and stability.